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Response to Prof. Borgstro¨m re: paper
by Arvidsson et al. (Respir Med 2000;
94: 574–577)
We have received the letter by Prof. Borgstrom, employed
by AstraZeneca R&D in Lund, regarding our recently
published study comparing the effects of salbutamol given
either by the Turbuhaler1 or the Diskus1 device (1). Prof.
Borgstro¨m is bringing up a series of unrelated issues, but
the key question is whether it is appropriate to use a
cumulative doss–response design when comparing the
clinical effects of bronchodilators.
Briefly, our study compared the effects of salbutamol
given by two different inhalation devices, the Turbuhaler1
and the Diskus1. We found that there were no, or very
small, differences in the bronchodilating effects of salbuta-
mol given by either device, in a dose range of 200–3200 mg.
Importantly, we documented a clear dose–response rela-
tionship in FEV1 over this dose range (2?2–2?5 l), which is
important when comparing the potency of treatments.Prof. Borgstro¨m argues that the initial dose of a b2-
agonist may influence the effects of a second dose, and thus
that the results of findings at the higher levels of the dose–
response curve may be more dicult to compare. Interest-
ingly, however, Astra’s documentation for the Turbuhaler1
is based on cumulative dose–response studies (2–5).
Futhermore, there is a massive published documentation
regarding the appropriateness of using cumulative dose–
response designs in bronchodilator studies. In addition to
these scientific arguments, it may however be even more
important to remember that asthma patients, in real life,
use multiple doses from an inhaler when they experience
worsening of asthma. Thus, cumulative dosing may very
well be appropriate when comparing the effects of different
inhaled drugs. Regardless of this, we found no difference in
the effects of salbutamol Turbuhaler1 or Diskus1 at the
lowest dose used (200mg). Also, a study performed in
Southampton, U.K., showed no clinically relevant differ-
ences in maximal bronchodilating effect when therapeutic
doses of salbutamol were given via Turbuhaler1 either as
two consecutive doses or as two divided doses separated by
different time intervals (6).
We were careful to compare the same microgram doses,
in contrast to some more recent publications evolved from
studies sponsored by AstraZeneca (7,8). We did this to
avoid any advantage for any of the used inhalers. Our
conclusion must be, however aggravating it may be for
Prof. Borgstro¨m, that there is no or little difference in the
effects of salbutamol given by either Turbuhaler1 or
Diskus1, in the types of patients we have included in the
present study.
Prof. Borgstro¨m had some additional comments. One of
these has been addressed in a recent erratum. Importantly,
it is not required to reference studies published only as
abstracts, as these have not been peer reviewed. It is
extensively argued that the Turbuhaler1 gives better
peripheral deposition than other devices, and in a publica-
tion by Thorson et al. at AstraZeneca, it is stated that ‘the
systemic availability of budesonide, calculated as a geo-
metric mean and expressed as percentage of the metered
dose, was 38% for Turbuhaler1 and 26% for p-MDI’ (9).
We are not stating that there is a greater peripheral to
central deposition, but rather a greater total peripheral lung
deposition, using the Turbuhaler1 device. This argument,
extensively used at scientific meeting and in marketing
situations, may however be untrue as described in Prof.
Borgstro¨m’s letter, thus arguing against any improved
therapeutic ratio of a drug given by Turbuhaler1 vs. any
other device.
Importantly, we have high respect for Prof. Borgstro¨m’s
competence in this field, but we feel that it also must be
important to consider clinical implications of studies
comparing different devices. ‘In vivo veritas’ as stated by
Prof. Borgstro¨m previously (10).
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